340B hospital program leads to higher costs, PhRMA says

The 340B Drug Pricing Program costs patients more in the long run by moving care to hospital outpatient settings rather than physicians' offices, according to a recent analysis commissioned by the drugmaker lobby Pharmaceutical Research and Manufacturers of America.